Cellect Biotechnology Ltd.
Cellect Biotechnology Ltd. (APOP) Stock Competitors & Peer Comparison
See (APOP) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| APOP | $13.17 | +0.38% | 129M | -15.42 | -$0.85 | N/A |
| VRTX | $388.94 | -1.56% | 99.7B | 27.63 | $14.07 | N/A |
| REGN | $572.38 | -2.90% | 59.6B | 14.43 | $39.67 | +0.46% |
| ALNY | $443.64 | -2.36% | 58.2B | -181.08 | -$2.45 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $677.32 | +2.62% | 41.4B | 34.43 | $19.67 | N/A |
| BNTX | $105.07 | -5.24% | 25.3B | -63.30 | -$1.66 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $26.27 | +0.27% | 19.5B | -26.01 | -$1.01 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
APOP vs VRTX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, VRTX has a market cap of 99.7B. Regarding current trading prices, APOP is priced at $13.17, while VRTX trades at $388.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas VRTX's P/E ratio is 27.63. In terms of profitability, APOP's ROE is -0.01%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, APOP is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check VRTX's competition here
APOP vs REGN Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, REGN has a market cap of 59.6B. Regarding current trading prices, APOP is priced at $13.17, while REGN trades at $572.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas REGN's P/E ratio is 14.43. In terms of profitability, APOP's ROE is -0.01%, compared to REGN's ROE of +0.15%. Regarding short-term risk, APOP is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check REGN's competition here
APOP vs ALNY Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, ALNY has a market cap of 58.2B. Regarding current trading prices, APOP is priced at $13.17, while ALNY trades at $443.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas ALNY's P/E ratio is -181.08. In terms of profitability, APOP's ROE is -0.01%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, APOP is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check ALNY's competition here
APOP vs SGEN Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, APOP is priced at $13.17, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas SGEN's P/E ratio is -57.19. In terms of profitability, APOP's ROE is -0.01%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, APOP is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check SGEN's competition here
APOP vs ARGX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, ARGX has a market cap of 41.4B. Regarding current trading prices, APOP is priced at $13.17, while ARGX trades at $677.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas ARGX's P/E ratio is 34.43. In terms of profitability, APOP's ROE is -0.01%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, APOP is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check ARGX's competition here
APOP vs BNTX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, BNTX has a market cap of 25.3B. Regarding current trading prices, APOP is priced at $13.17, while BNTX trades at $105.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas BNTX's P/E ratio is -63.30. In terms of profitability, APOP's ROE is -0.01%, compared to BNTX's ROE of -0.02%. Regarding short-term risk, APOP is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check BNTX's competition here
APOP vs BGNE Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, APOP is priced at $13.17, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas BGNE's P/E ratio is -22.55. In terms of profitability, APOP's ROE is -0.01%, compared to BGNE's ROE of -0.05%. Regarding short-term risk, APOP is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check BGNE's competition here
APOP vs SMMT Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, SMMT has a market cap of 19.5B. Regarding current trading prices, APOP is priced at $13.17, while SMMT trades at $26.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas SMMT's P/E ratio is -26.01. In terms of profitability, APOP's ROE is -0.01%, compared to SMMT's ROE of -2.09%. Regarding short-term risk, APOP is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check SMMT's competition here
APOP vs DNA-WT Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, APOP is priced at $13.17, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, APOP's ROE is -0.01%, compared to DNA-WT's ROE of -0.45%. Regarding short-term risk, APOP is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check DNA-WT's competition here
APOP vs INCY Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, INCY has a market cap of 16.6B. Regarding current trading prices, APOP is priced at $13.17, while INCY trades at $84.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas INCY's P/E ratio is 20.04. In terms of profitability, APOP's ROE is -0.01%, compared to INCY's ROE of +0.24%. Regarding short-term risk, APOP is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check INCY's competition here
APOP vs RPRX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, RPRX has a market cap of 15.6B. Regarding current trading prices, APOP is priced at $13.17, while RPRX trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas RPRX's P/E ratio is 15.71. In terms of profitability, APOP's ROE is -0.01%, compared to RPRX's ROE of +0.15%. Regarding short-term risk, APOP is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check RPRX's competition here
APOP vs GMAB Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, GMAB has a market cap of 15.3B. Regarding current trading prices, APOP is priced at $13.17, while GMAB trades at $24.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas GMAB's P/E ratio is 12.60. In terms of profitability, APOP's ROE is -0.01%, compared to GMAB's ROE of +0.28%. Regarding short-term risk, APOP is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check GMAB's competition here
APOP vs UTHR Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, UTHR has a market cap of 13.8B. Regarding current trading prices, APOP is priced at $13.17, while UTHR trades at $305.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas UTHR's P/E ratio is 11.91. In terms of profitability, APOP's ROE is -0.01%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, APOP is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check UTHR's competition here
APOP vs KRTX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, APOP is priced at $13.17, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas KRTX's P/E ratio is -28.09. In terms of profitability, APOP's ROE is -0.01%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, APOP is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check KRTX's competition here
APOP vs ASND Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, ASND has a market cap of 11.5B. Regarding current trading prices, APOP is priced at $13.17, while ASND trades at $190.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas ASND's P/E ratio is -36.05. In terms of profitability, APOP's ROE is -0.01%, compared to ASND's ROE of +1.52%. Regarding short-term risk, APOP is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check ASND's competition here
APOP vs BMRN Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, BMRN has a market cap of 11.2B. Regarding current trading prices, APOP is priced at $13.17, while BMRN trades at $58.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas BMRN's P/E ratio is 17.26. In terms of profitability, APOP's ROE is -0.01%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, APOP is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check BMRN's competition here
APOP vs EXEL Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, EXEL has a market cap of 10.2B. Regarding current trading prices, APOP is priced at $13.17, while EXEL trades at $37.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas EXEL's P/E ratio is 18.22. In terms of profitability, APOP's ROE is -0.01%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, APOP is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check EXEL's competition here
APOP vs MRNA Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, MRNA has a market cap of 9.9B. Regarding current trading prices, APOP is priced at $13.17, while MRNA trades at $25.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas MRNA's P/E ratio is -3.38. In terms of profitability, APOP's ROE is -0.01%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, APOP is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check MRNA's competition here
APOP vs RXDX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, APOP is priced at $13.17, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas RXDX's P/E ratio is -56.47. In terms of profitability, APOP's ROE is -0.01%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, APOP is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check RXDX's competition here
APOP vs MDGL Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, MDGL has a market cap of 9.2B. Regarding current trading prices, APOP is priced at $13.17, while MDGL trades at $412.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas MDGL's P/E ratio is -32.59. In terms of profitability, APOP's ROE is -0.01%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, APOP is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check MDGL's competition here
APOP vs BBIO Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, BBIO has a market cap of 9B. Regarding current trading prices, APOP is priced at $13.17, while BBIO trades at $47.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas BBIO's P/E ratio is -11.45. In terms of profitability, APOP's ROE is -0.01%, compared to BBIO's ROE of +0.51%. Regarding short-term risk, APOP is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check BBIO's competition here
APOP vs VRNA Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, VRNA has a market cap of 9B. Regarding current trading prices, APOP is priced at $13.17, while VRNA trades at $105.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas VRNA's P/E ratio is -100.59. In terms of profitability, APOP's ROE is -0.01%, compared to VRNA's ROE of -0.39%. Regarding short-term risk, APOP is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check VRNA's competition here
APOP vs TECH Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, TECH has a market cap of 8.9B. Regarding current trading prices, APOP is priced at $13.17, while TECH trades at $56.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas TECH's P/E ratio is 123.28. In terms of profitability, APOP's ROE is -0.01%, compared to TECH's ROE of +0.06%. Regarding short-term risk, APOP is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check TECH's competition here
APOP vs IMGN Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, APOP is priced at $13.17, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas IMGN's P/E ratio is -111.55. In terms of profitability, APOP's ROE is -0.01%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, APOP is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check IMGN's competition here
APOP vs HALO Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, HALO has a market cap of 8.4B. Regarding current trading prices, APOP is priced at $13.17, while HALO trades at $72.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas HALO's P/E ratio is 16.52. In terms of profitability, APOP's ROE is -0.01%, compared to HALO's ROE of +1.37%. Regarding short-term risk, APOP is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check HALO's competition here
APOP vs BPMC Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, APOP is priced at $13.17, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas BPMC's P/E ratio is -51.58. In terms of profitability, APOP's ROE is -0.01%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, APOP is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check BPMC's competition here
APOP vs CERE Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, APOP is priced at $13.17, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas CERE's P/E ratio is -16.47. In terms of profitability, APOP's ROE is -0.01%, compared to CERE's ROE of -0.72%. Regarding short-term risk, APOP is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check CERE's competition here
APOP vs ROIV Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, ROIV has a market cap of 7.9B. Regarding current trading prices, APOP is priced at $13.17, while ROIV trades at $11.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas ROIV's P/E ratio is -10.68. In terms of profitability, APOP's ROE is -0.01%, compared to ROIV's ROE of -0.10%. Regarding short-term risk, APOP is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check ROIV's competition here
APOP vs ROIVW Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, APOP is priced at $13.17, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, APOP's ROE is -0.01%, compared to ROIVW's ROE of -0.10%. Regarding short-term risk, APOP is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check ROIVW's competition here
APOP vs JAZZ Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, JAZZ has a market cap of 7.6B. Regarding current trading prices, APOP is priced at $13.17, while JAZZ trades at $124.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas JAZZ's P/E ratio is -17.85. In terms of profitability, APOP's ROE is -0.01%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, APOP is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check JAZZ's competition here
APOP vs CORT Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, CORT has a market cap of 7.3B. Regarding current trading prices, APOP is priced at $13.17, while CORT trades at $68.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas CORT's P/E ratio is 61.45. In terms of profitability, APOP's ROE is -0.01%, compared to CORT's ROE of +0.20%. Regarding short-term risk, APOP is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check CORT's competition here
APOP vs RVMD Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, RVMD has a market cap of 6.7B. Regarding current trading prices, APOP is priced at $13.17, while RVMD trades at $35.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas RVMD's P/E ratio is -7.89. In terms of profitability, APOP's ROE is -0.01%, compared to RVMD's ROE of -0.42%. Regarding short-term risk, APOP is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check RVMD's competition here
APOP vs IONS Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, IONS has a market cap of 6.7B. Regarding current trading prices, APOP is priced at $13.17, while IONS trades at $41.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas IONS's P/E ratio is -23.76. In terms of profitability, APOP's ROE is -0.01%, compared to IONS's ROE of -0.45%. Regarding short-term risk, APOP is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check IONS's competition here
APOP vs RYTM Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, RYTM has a market cap of 6.6B. Regarding current trading prices, APOP is priced at $13.17, while RYTM trades at $99.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas RYTM's P/E ratio is -32.96. In terms of profitability, APOP's ROE is -0.01%, compared to RYTM's ROE of -1.55%. Regarding short-term risk, APOP is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check RYTM's competition here
APOP vs RETA Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, APOP is priced at $13.17, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas RETA's P/E ratio is -66.29. In terms of profitability, APOP's ROE is -0.01%, compared to RETA's ROE of +0.47%. Regarding short-term risk, APOP is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check RETA's competition here
APOP vs ABVX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, ABVX has a market cap of 5.9B. Regarding current trading prices, APOP is priced at $13.17, while ABVX trades at $77.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas ABVX's P/E ratio is -22.52. In terms of profitability, APOP's ROE is -0.01%, compared to ABVX's ROE of -1.62%. Regarding short-term risk, APOP is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check ABVX's competition here
APOP vs RNA Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, RNA has a market cap of 5.8B. Regarding current trading prices, APOP is priced at $13.17, while RNA trades at $45.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas RNA's P/E ratio is -12.72. In terms of profitability, APOP's ROE is -0.01%, compared to RNA's ROE of -0.33%. Regarding short-term risk, APOP is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check RNA's competition here
APOP vs AXSM Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, AXSM has a market cap of 5.8B. Regarding current trading prices, APOP is priced at $13.17, while AXSM trades at $116.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas AXSM's P/E ratio is -22.99. In terms of profitability, APOP's ROE is -0.01%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, APOP is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check AXSM's competition here
APOP vs ABCM Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, APOP is priced at $13.17, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, APOP's ROE is -0.01%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, APOP is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check ABCM's competition here
APOP vs ISEE Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, APOP is priced at $13.17, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas ISEE's P/E ratio is -22.44. In terms of profitability, APOP's ROE is -0.01%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, APOP is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check ISEE's competition here
APOP vs NUVL Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, NUVL has a market cap of 5.3B. Regarding current trading prices, APOP is priced at $13.17, while NUVL trades at $74.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas NUVL's P/E ratio is -15.05. In terms of profitability, APOP's ROE is -0.01%, compared to NUVL's ROE of -0.33%. Regarding short-term risk, APOP is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check NUVL's competition here
APOP vs MRUS Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, MRUS has a market cap of 5B. Regarding current trading prices, APOP is priced at $13.17, while MRUS trades at $65.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas MRUS's P/E ratio is -11.78. In terms of profitability, APOP's ROE is -0.01%, compared to MRUS's ROE of -0.55%. Regarding short-term risk, APOP is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check MRUS's competition here
APOP vs CRSP Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, APOP is priced at $13.17, while CRSP trades at $54.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas CRSP's P/E ratio is -10.02. In terms of profitability, APOP's ROE is -0.01%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, APOP is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check CRSP's competition here
APOP vs ALKS Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, APOP is priced at $13.17, while ALKS trades at $29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas ALKS's P/E ratio is 14.01. In terms of profitability, APOP's ROE is -0.01%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, APOP is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check ALKS's competition here
APOP vs TGTX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, TGTX has a market cap of 4.5B. Regarding current trading prices, APOP is priced at $13.17, while TGTX trades at $28.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas TGTX's P/E ratio is 75.08. In terms of profitability, APOP's ROE is -0.01%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, APOP is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check TGTX's competition here
APOP vs ALPN Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, APOP is priced at $13.17, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas ALPN's P/E ratio is -101.52. In terms of profitability, APOP's ROE is -0.01%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, APOP is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check ALPN's competition here
APOP vs CYTK Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, CYTK has a market cap of 4.4B. Regarding current trading prices, APOP is priced at $13.17, while CYTK trades at $37.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas CYTK's P/E ratio is -7.23. In terms of profitability, APOP's ROE is -0.01%, compared to CYTK's ROE of +3.09%. Regarding short-term risk, APOP is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check CYTK's competition here
APOP vs ACAD Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, APOP is priced at $13.17, while ACAD trades at $25.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas ACAD's P/E ratio is 19.04. In terms of profitability, APOP's ROE is -0.01%, compared to ACAD's ROE of +0.31%. Regarding short-term risk, APOP is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check ACAD's competition here
APOP vs KRYS Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, KRYS has a market cap of 4.2B. Regarding current trading prices, APOP is priced at $13.17, while KRYS trades at $146.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas KRYS's P/E ratio is 29.83. In terms of profitability, APOP's ROE is -0.01%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, APOP is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check KRYS's competition here
APOP vs OPT Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, APOP is priced at $13.17, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas OPT's P/E ratio is -1.52. In terms of profitability, APOP's ROE is -0.01%, compared to OPT's ROE of +2.60%. Regarding short-term risk, APOP is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check OPT's competition here
APOP vs TLX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, TLX has a market cap of 4.1B. Regarding current trading prices, APOP is priced at $13.17, while TLX trades at $12.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas TLX's P/E ratio is 610.00. In terms of profitability, APOP's ROE is -0.01%, compared to TLX's ROE of +0.10%. Regarding short-term risk, APOP is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check TLX's competition here
APOP vs MRTX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, APOP is priced at $13.17, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas MRTX's P/E ratio is -4.82. In terms of profitability, APOP's ROE is -0.01%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, APOP is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check MRTX's competition here
APOP vs ADMA Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, ADMA has a market cap of 4.1B. Regarding current trading prices, APOP is priced at $13.17, while ADMA trades at $17.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas ADMA's P/E ratio is 20.01. In terms of profitability, APOP's ROE is -0.01%, compared to ADMA's ROE of +0.62%. Regarding short-term risk, APOP is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check ADMA's competition here
APOP vs AAPG Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, AAPG has a market cap of 4B. Regarding current trading prices, APOP is priced at $13.17, while AAPG trades at $43.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas AAPG's P/E ratio is -21.44. In terms of profitability, APOP's ROE is -0.01%, compared to AAPG's ROE of -0.79%. Regarding short-term risk, APOP is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check AAPG's competition here
APOP vs PCVX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, PCVX has a market cap of 4B. Regarding current trading prices, APOP is priced at $13.17, while PCVX trades at $30.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas PCVX's P/E ratio is -7.41. In terms of profitability, APOP's ROE is -0.01%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, APOP is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check PCVX's competition here
APOP vs PTCT Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, APOP is priced at $13.17, while PTCT trades at $49.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas PTCT's P/E ratio is 6.99. In terms of profitability, APOP's ROE is -0.01%, compared to PTCT's ROE of -0.99%. Regarding short-term risk, APOP is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check PTCT's competition here
APOP vs ACLX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, ACLX has a market cap of 3.8B. Regarding current trading prices, APOP is priced at $13.17, while ACLX trades at $68.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas ACLX's P/E ratio is -20.09. In terms of profitability, APOP's ROE is -0.01%, compared to ACLX's ROE of -0.43%. Regarding short-term risk, APOP is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check ACLX's competition here
APOP vs AKRO Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, AKRO has a market cap of 3.8B. Regarding current trading prices, APOP is priced at $13.17, while AKRO trades at $47.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas AKRO's P/E ratio is -12.34. In terms of profitability, APOP's ROE is -0.01%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, APOP is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check AKRO's competition here
APOP vs RYZB Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, APOP is priced at $13.17, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas RYZB's P/E ratio is -57.86. In terms of profitability, APOP's ROE is -0.01%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, APOP is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check RYZB's competition here
APOP vs ZLAB Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, ZLAB has a market cap of 3.7B. Regarding current trading prices, APOP is priced at $13.17, while ZLAB trades at $34.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas ZLAB's P/E ratio is -17.01. In terms of profitability, APOP's ROE is -0.01%, compared to ZLAB's ROE of -0.27%. Regarding short-term risk, APOP is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check ZLAB's competition here
APOP vs CBAY Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, APOP is priced at $13.17, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas CBAY's P/E ratio is -32.81. In terms of profitability, APOP's ROE is -0.01%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, APOP is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check CBAY's competition here
APOP vs MIRM Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, MIRM has a market cap of 3.6B. Regarding current trading prices, APOP is priced at $13.17, while MIRM trades at $71.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas MIRM's P/E ratio is -59.35. In terms of profitability, APOP's ROE is -0.01%, compared to MIRM's ROE of -0.25%. Regarding short-term risk, APOP is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check MIRM's competition here
APOP vs SWTX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, APOP is priced at $13.17, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas SWTX's P/E ratio is -13.78. In terms of profitability, APOP's ROE is -0.01%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, APOP is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check SWTX's competition here
APOP vs PTGX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, PTGX has a market cap of 3.5B. Regarding current trading prices, APOP is priced at $13.17, while PTGX trades at $56.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas PTGX's P/E ratio is 77.92. In terms of profitability, APOP's ROE is -0.01%, compared to PTGX's ROE of +0.08%. Regarding short-term risk, APOP is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check PTGX's competition here
APOP vs SLNO Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, SLNO has a market cap of 3.5B. Regarding current trading prices, APOP is priced at $13.17, while SLNO trades at $66.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas SLNO's P/E ratio is -15.75. In terms of profitability, APOP's ROE is -0.01%, compared to SLNO's ROE of -0.74%. Regarding short-term risk, APOP is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check SLNO's competition here
APOP vs APLS Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, APLS has a market cap of 3.5B. Regarding current trading prices, APOP is priced at $13.17, while APLS trades at $27.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas APLS's P/E ratio is -15.04. In terms of profitability, APOP's ROE is -0.01%, compared to APLS's ROE of -1.16%. Regarding short-term risk, APOP is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check APLS's competition here
APOP vs MLTX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, MLTX has a market cap of 3.5B. Regarding current trading prices, APOP is priced at $13.17, while MLTX trades at $54.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas MLTX's P/E ratio is -19.58. In terms of profitability, APOP's ROE is -0.01%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, APOP is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check MLTX's competition here
APOP vs MTSR Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, MTSR has a market cap of 3.4B. Regarding current trading prices, APOP is priced at $13.17, while MTSR trades at $32.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas MTSR's P/E ratio is -11.12. In terms of profitability, APOP's ROE is -0.01%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, APOP is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check MTSR's competition here
APOP vs SRRK Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, SRRK has a market cap of 3.2B. Regarding current trading prices, APOP is priced at $13.17, while SRRK trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas SRRK's P/E ratio is -11.41. In terms of profitability, APOP's ROE is -0.01%, compared to SRRK's ROE of -1.27%. Regarding short-term risk, APOP is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check SRRK's competition here
APOP vs LEGN Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, LEGN has a market cap of 3.2B. Regarding current trading prices, APOP is priced at $13.17, while LEGN trades at $34.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas LEGN's P/E ratio is -19.44. In terms of profitability, APOP's ROE is -0.01%, compared to LEGN's ROE of -0.31%. Regarding short-term risk, APOP is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check LEGN's competition here
APOP vs LGND Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, LGND has a market cap of 3.1B. Regarding current trading prices, APOP is priced at $13.17, while LGND trades at $158.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas LGND's P/E ratio is -39.30. In terms of profitability, APOP's ROE is -0.01%, compared to LGND's ROE of -0.09%. Regarding short-term risk, APOP is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check LGND's competition here
APOP vs KYMR Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, KYMR has a market cap of 3B. Regarding current trading prices, APOP is priced at $13.17, while KYMR trades at $41.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas KYMR's P/E ratio is -11.98. In terms of profitability, APOP's ROE is -0.01%, compared to KYMR's ROE of -0.32%. Regarding short-term risk, APOP is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check KYMR's competition here
APOP vs XENE Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, XENE has a market cap of 2.9B. Regarding current trading prices, APOP is priced at $13.17, while XENE trades at $38.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas XENE's P/E ratio is -10.74. In terms of profitability, APOP's ROE is -0.01%, compared to XENE's ROE of -0.39%. Regarding short-term risk, APOP is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check XENE's competition here
APOP vs VKTX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, VKTX has a market cap of 2.9B. Regarding current trading prices, APOP is priced at $13.17, while VKTX trades at $25.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas VKTX's P/E ratio is -16.79. In terms of profitability, APOP's ROE is -0.01%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, APOP is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check VKTX's competition here
APOP vs ARWR Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, ARWR has a market cap of 2.9B. Regarding current trading prices, APOP is priced at $13.17, while ARWR trades at $20.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas ARWR's P/E ratio is -17.26. In terms of profitability, APOP's ROE is -0.01%, compared to ARWR's ROE of -0.41%. Regarding short-term risk, APOP is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check ARWR's competition here
APOP vs MORF Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, APOP is priced at $13.17, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas MORF's P/E ratio is -14.88. In terms of profitability, APOP's ROE is -0.01%, compared to MORF's ROE of -0.16%. Regarding short-term risk, APOP is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check MORF's competition here
APOP vs MOR Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, APOP is priced at $13.17, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas MOR's P/E ratio is -12.64. In terms of profitability, APOP's ROE is -0.01%, compared to MOR's ROE of -1.84%. Regarding short-term risk, APOP is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check MOR's competition here
APOP vs CRNX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, APOP is priced at $13.17, while CRNX trades at $30.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas CRNX's P/E ratio is -7.34. In terms of profitability, APOP's ROE is -0.01%, compared to CRNX's ROE of -0.32%. Regarding short-term risk, APOP is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check CRNX's competition here
APOP vs RARE Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, RARE has a market cap of 2.8B. Regarding current trading prices, APOP is priced at $13.17, while RARE trades at $29.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas RARE's P/E ratio is -5.34. In terms of profitability, APOP's ROE is -0.01%, compared to RARE's ROE of -2.37%. Regarding short-term risk, APOP is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check RARE's competition here
APOP vs NAMS Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, NAMS has a market cap of 2.8B. Regarding current trading prices, APOP is priced at $13.17, while NAMS trades at $24.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas NAMS's P/E ratio is -15.53. In terms of profitability, APOP's ROE is -0.01%, compared to NAMS's ROE of -0.25%. Regarding short-term risk, APOP is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check NAMS's competition here
APOP vs KDNY Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, APOP is priced at $13.17, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas KDNY's P/E ratio is -12.47. In terms of profitability, APOP's ROE is -0.01%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, APOP is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check KDNY's competition here
APOP vs MYOV Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, APOP is priced at $13.17, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas MYOV's P/E ratio is -14.05. In terms of profitability, APOP's ROE is -0.01%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, APOP is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check MYOV's competition here
APOP vs IMVT Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, IMVT has a market cap of 2.6B. Regarding current trading prices, APOP is priced at $13.17, while IMVT trades at $14.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas IMVT's P/E ratio is -5.24. In terms of profitability, APOP's ROE is -0.01%, compared to IMVT's ROE of -0.84%. Regarding short-term risk, APOP is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check IMVT's competition here
APOP vs CPRX Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, CPRX has a market cap of 2.5B. Regarding current trading prices, APOP is priced at $13.17, while CPRX trades at $20.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas CPRX's P/E ratio is 12.50. In terms of profitability, APOP's ROE is -0.01%, compared to CPRX's ROE of +0.27%. Regarding short-term risk, APOP is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check CPRX's competition here
APOP vs KNSA Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, KNSA has a market cap of 2.4B. Regarding current trading prices, APOP is priced at $13.17, while KNSA trades at $33.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas KNSA's P/E ratio is 660.80. In terms of profitability, APOP's ROE is -0.01%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, APOP is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check KNSA's competition here
APOP vs TARS Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, TARS has a market cap of 2.4B. Regarding current trading prices, APOP is priced at $13.17, while TARS trades at $56.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas TARS's P/E ratio is -24.72. In terms of profitability, APOP's ROE is -0.01%, compared to TARS's ROE of -0.32%. Regarding short-term risk, APOP is less volatile compared to TARS. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check TARS's competition here
APOP vs PRVB Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, APOP is priced at $13.17, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas PRVB's P/E ratio is -16.43. In terms of profitability, APOP's ROE is -0.01%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, APOP is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check PRVB's competition here
APOP vs LBPH Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, APOP is priced at $13.17, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas LBPH's P/E ratio is -26.66. In terms of profitability, APOP's ROE is -0.01%, compared to LBPH's ROE of -0.21%. Regarding short-term risk, APOP is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check LBPH's competition here
APOP vs VCYT Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, VCYT has a market cap of 2.3B. Regarding current trading prices, APOP is priced at $13.17, while VCYT trades at $29.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas VCYT's P/E ratio is 86.91. In terms of profitability, APOP's ROE is -0.01%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, APOP is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check VCYT's competition here
APOP vs FOLD Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, FOLD has a market cap of 2.3B. Regarding current trading prices, APOP is priced at $13.17, while FOLD trades at $7.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas FOLD's P/E ratio is -62.33. In terms of profitability, APOP's ROE is -0.01%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, APOP is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check FOLD's competition here
APOP vs CNTA Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, CNTA has a market cap of 2.3B. Regarding current trading prices, APOP is priced at $13.17, while CNTA trades at $17.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas CNTA's P/E ratio is -9.19. In terms of profitability, APOP's ROE is -0.01%, compared to CNTA's ROE of -0.56%. Regarding short-term risk, APOP is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check CNTA's competition here
APOP vs DNLI Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, DNLI has a market cap of 2.3B. Regarding current trading prices, APOP is priced at $13.17, while DNLI trades at $15.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas DNLI's P/E ratio is -5.54. In terms of profitability, APOP's ROE is -0.01%, compared to DNLI's ROE of -0.41%. Regarding short-term risk, APOP is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check DNLI's competition here
APOP vs DICE Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, APOP is priced at $13.17, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas DICE's P/E ratio is -21.91. In terms of profitability, APOP's ROE is -0.01%, compared to DICE's ROE of +0.56%. Regarding short-term risk, APOP is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for APOP.Check DICE's competition here
APOP vs LQDA Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, LQDA has a market cap of 2.3B. Regarding current trading prices, APOP is priced at $13.17, while LQDA trades at $26.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas LQDA's P/E ratio is -14.42. In terms of profitability, APOP's ROE is -0.01%, compared to LQDA's ROE of -1.58%. Regarding short-term risk, APOP is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check LQDA's competition here
APOP vs APGE Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, APOP is priced at $13.17, while APGE trades at $36.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas APGE's P/E ratio is -8.92. In terms of profitability, APOP's ROE is -0.01%, compared to APGE's ROE of -0.23%. Regarding short-term risk, APOP is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check APGE's competition here
APOP vs IDYA Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, IDYA has a market cap of 2.2B. Regarding current trading prices, APOP is priced at $13.17, while IDYA trades at $24.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas IDYA's P/E ratio is -6.43. In terms of profitability, APOP's ROE is -0.01%, compared to IDYA's ROE of -0.31%. Regarding short-term risk, APOP is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check IDYA's competition here
APOP vs AGIO Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, AGIO has a market cap of 2.2B. Regarding current trading prices, APOP is priced at $13.17, while AGIO trades at $37.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas AGIO's P/E ratio is 3.30. In terms of profitability, APOP's ROE is -0.01%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, APOP is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check AGIO's competition here
APOP vs HRMY Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, HRMY has a market cap of 2.2B. Regarding current trading prices, APOP is priced at $13.17, while HRMY trades at $37.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas HRMY's P/E ratio is 12.07. In terms of profitability, APOP's ROE is -0.01%, compared to HRMY's ROE of +0.26%. Regarding short-term risk, APOP is less volatile compared to HRMY. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check HRMY's competition here
APOP vs CALT Comparison August 2025
APOP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APOP stands at 129M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, APOP is priced at $13.17, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APOP currently has a P/E ratio of -15.42, whereas CALT's P/E ratio is -22.73. In terms of profitability, APOP's ROE is -0.01%, compared to CALT's ROE of -1.67%. Regarding short-term risk, APOP is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for APOP.Check CALT's competition here